Your session is about to expire
← Back to Search
Selumetinib + Olaparib for Cancer
Study Summary
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 2 trial • 37 Patients • NCT01085214Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a lot of lung disease in both sides of your lungs as shown on a special type of X-ray called HRCT scan.My side effects from previous treatments are mild, except for hair loss.I haven't had chemotherapy or radiotherapy (except for comfort care) in the last 3 weeks.I am currently taking certain medications.I have had cancer before, but it fits the exceptions listed.My brain or spinal metastases have been stable for 4 weeks without steroids or seizure meds.I am currently experiencing symptoms of lung inflammation.I am using two effective birth control methods.I will use a condom during and for 3 months after treatment if my partner could get pregnant.I cannot swallow pills or have a stomach condition that affects medication absorption.I have not taken MEK inhibitors for my condition.I have had multiple chemotherapy treatments.I am fully active or restricted in physically strenuous activity but can do light work.I have not had major surgery in the last 4 weeks or minor surgery in the last 2 weeks.A) You have advanced or recurrent ovarian or endometrial cancer, or another type of solid tumor, and have not responded well to previous treatment.
B) Your disease can be measured and biopsied.
C) You are willing to have a biopsy.
D) You have received treatment with PARP inhibitors before.I have been diagnosed with or show signs of myelodysplastic syndrome or acute myeloid leukemia.I am not pregnant, breastfeeding, or if capable of becoming pregnant, I am using birth control.My heart condition fits the specified criteria.I have had a bone marrow or double cord blood transplant.My advanced cancer has not responded to standard treatments or has come back after such treatments.I have at least one tumor that can be measured.My organs and bone marrow are functioning well.I am willing and able to follow the study's requirements, including treatments and visits.I am postmenopausal or cannot become pregnant.I am not using other cancer treatments or live vaccines while on the study medication.I do not have any severe or uncontrolled illnesses.I have specific gene changes and may have been treated with MEK or PARP inhibitors.I am 18 years old or older.I don't have lasting side effects from cancer treatment, except for hair loss.I have ovarian cancer with symptoms like fluid buildup, even if tumors can't be measured.You are expected to live for at least 16 weeks.You have certain eye conditions as listed in the study requirements.I have not received a whole blood transfusion in the last 4 months.I am not allergic to selumetinib, olaparib, or similar medications.People with weakened immune systems, such as those who are HIV-positive, cannot participate in the study.
- Group 1: Endometrial Cancer with RPA
- Group 2: Selumetinib + Olaparib
- Group 3: Solid Tumors that Harbor Somatic RPA
- Group 4: Ovarian Cancer with RPA
- Group 5: Ovarian Cancer-Progression-prior PARP Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what maladies is Selumetinib typically deployed?
"Selumetinib can be employed to help with pharmacotherapy, advance directives, and malignant neoplasm of ovary."
Is this the inaugural exploration of its type?
"Selumetinib was initially tested in 2005, with AstraZeneca providing the necessary funds. This initial trial, which included 98 participants, established Selumetinib's eligibility for Phase 1 drug approval. Nowadays there are 217 live trials of this medication across a plethora of cities and countries - 60 to be exact."
How many participants are involved in the current research?
"Unfortunately, this clinical trial is not presently accepting candidates. It was first published on August 4th 2017 and has undergone its most recent edit on August 31st 2022. If you are investigating other studies, there are 4711 trials that involve neoplasms looking for participants and 217 research opportunities studying the effects of Selumetinib."
Are there still opportunities for individuals to join this trial?
"At the moment, no patients are being accepted into this trial. It was originally posted on August 4th 2017 and last updated 8/31/2022,. If you're looking for alternative studies to participate in, there are currently 4711 trials recruiting neoplasm sufferers and 217 clinical trials seeking participants who require Selumetinib treatment."
Could you elaborate on the prior research conducted with Selumetinib?
"At present, 217 different Selumetinib studies are ongoing with 32 in Phase 3. While there is a significant presence of these trials in Houston, Texas, 1000 other locations have clinical trials for this medication running."
What adverse effects does Selumetinib pose to individuals?
"Selumetinib is rated a 1 on the safety scale since this is an early phase trial, meaning there are only small amounts of data demonstrating efficacy and security."
Share this study with friends
Copy Link
Messenger